REMEGEN's stock price soared 10.04% during intraday trading on Monday, driven by the company's release of robust 2025 annual financial results.

The company reported a significant revenue increase of 89.55% year-on-year to RMB 3.242 billion and achieved a notable profit turnaround, with net profit attributable to owners reaching RMB 710 million compared to a loss of RMB 1.468 billion in the prior year. This performance was primarily fueled by strong sales growth of its key commercial products, Telitacicept for autoimmune diseases and Disitamab Vedotin for anti-tumor therapy.

Analysts from Huatai Securities highlighted REMEGEN's improving overseas potential and domestic business outlook. The pipeline is advancing steadily, with multiple Phase III trials expected to commence and key drug approvals anticipated in 2026. Additionally, revenue is projected to receive further support from upfront payments of licensing deals and the achievement of clinical milestones, particularly for RC148.